Zhitong Finance App News, Yiming Onko-B (01541.HK) announced that the Group has obtained approval from the US Food and Drug Administration for IMM0306's experimental new drug (IND) application for phase IB/II clinical trials to treat systemic lupus erythematosus (SLE).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.